Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNK01 with Chemotherapy in Advanced NSCLC
NCT04872634Phase 2Unknown
- Sponsor
- NKMax Co., Ltd.
- Start
- Jul 2021
- Primary completion
- May 2023
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of troculeucel in non-small cell lung cancer (NSCLC), sponsored by NKMax Co., Ltd.. Status: unknown.
02
Drugs
troculeucel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04872634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04872634.